Literature DB >> 31902352

Role of Drug-metabolizing Enzymes in Cancer and Cancer Therapy.

Siqi Feng1, Anqi Li1, Yi-Chao Zheng1, Hong-Min Liu1.   

Abstract

BACKGROUND: Cancer is one of the most serious diseases threatening human health with high morbidity and mortality in the world. For the treatment of cancer, chemotherapy is one of the most widely used strategies, for almost all kinds of tumors and diverse stages of tumor development. The efficacy of chemotherapy not only depends on the activity of the drug administrated but also on whether the compound could reach the effective therapeutic concentration in tumor cells. Therefore, expression and activity of drug-metabolizing enzymes (DMEs) in tumor tissues and metabolic organs of cancer patients are important for the dispositional behavior of anticancer drugs as well as the clinical response of chemotherapy.
METHODS: This review summarizes the recent advancement of the DMEs expression and activity in various cancers, as well as the potential regulatory mechanisms of major DMEs in cancer and cancer therapy.
RESULTS: Compared to normal tissues, expression and activity of major DMEs are significantly dysregulated in patients by various factors including epigenetic modification, ligand-activated transcriptional regulation and signaling pathways. Additionally, DMEs play an important role in anticancer drug efficacy, chemoresistance as well as the activation of prodrugs.
CONCLUSION: This review reinforces a more comprehensive understanding of DMEs in cancer and cancer therapy, and provides more opportunities for cancer therapy. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Drug-metabolizing enzymes; cancer; cancer therapy; epigenetic modification; ligand-activated transcriptional regulation; signaling pathways.

Mesh:

Substances:

Year:  2020        PMID: 31902352     DOI: 10.2174/1389200221666200103111053

Source DB:  PubMed          Journal:  Curr Drug Metab        ISSN: 1389-2002            Impact factor:   3.731


  2 in total

Review 1.  Withaferin A in the Treatment of Liver Diseases: Progress and Pharmacokinetic Insights.

Authors:  Yangliu Xia; Mingrui Yan; Ping Wang; Keisuke Hamada; Nana Yan; Haiping Hao; Frank J Gonzalez; Tingting Yan
Journal:  Drug Metab Dispos       Date:  2021-12-13       Impact factor: 3.579

2.  Metabolism and Interspecies Variation of IMMH-010, a Programmed Cell Death Ligand 1 Inhibitor Prodrug.

Authors:  Yuchen Wang; Xiao Liu; Xiaowen Zou; Shuting Wang; Lijun Luo; Yuke Liu; Kai Dong; Xiaoqing Yao; Yan Li; Xiaoguang Chen; Li Sheng
Journal:  Pharmaceutics       Date:  2021-04-21       Impact factor: 6.321

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.